Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Shaping the battlefield: EGFR and KRAS tumor mutations' role on the immune microenvironment and immunotherapy responses in lung cancer.

Cancer metastasis reviews - 17 Jun 2025

Alsaed Bassel, Bobik Nina, Laitinen Hanna, Nandikonda Tanvi, Ilonen Ilkka, Haikala Heidi M

Abstract excerpt

The two most common and mutually exclusive driver mutations in non-small cell lung cancer affect EGFR and KRAS oncogenes. While EGFR mutations typically arise in non-smokers and are correlated with non-inflamed tumor microenvironment, KRAS mutations are associated with tobacco smoking, high mutational burden, and immunologically more active tumors. Consequently, current cancer immunotherapies have failed in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to KRAS gene

Share to Immunotherapy

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 40524071
DOI: 10.1007/s10555-025-10272-4
PMCID: PMC12170712

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Shaping the battlefield: EGFR and KRAS tumor mutations' role on the immune microenvironment and immunotherapy responses in lung cancer.PMID 40524071Read ↗

Unveiling the role of KRAS in tumor immune microenvironment.Semantic proximity Read ↗

EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment.Semantic proximity Read ↗

Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment.Semantic proximity Read ↗

The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer.Semantic proximity Read ↗

The landscape of responses to neoadjuvant immunotherapy in resectable Kirsten rat sarcoma viral oncogene homolog-mutant lung adenocarcinoma: Clinical heterogeneity and correlative immunologic analysis.Semantic proximity Read ↗

Immunotherapeutic targets in non‐small cell lung cancerSemantic proximity Read ↗

Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity.Semantic proximity Read ↗

KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of ImmunotherapySemantic proximity Read ↗

The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung CancerSemantic proximity Read ↗

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.Semantic proximity Read ↗

Tumor immune microenvironment in non-small cell lung cancer with EGFR mutation before and after EGFR-TKIs treatmentSemantic proximity Read ↗

Mutation-Driven Immune Microenvironments in Non-Small Cell Lung Cancer: Unrevealing Patterns through Cluster Analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.